The worldwide HIV/AIDS epidemic has generated intense criticism of pharmaceutical drug prices, a natural consequence of the industry's unique cost structure. Many people have proposed that the industry adopt what might be called a stakeholder model in place of the traditional profit-driven model. However, the rapid drop in HIV drug prices, combined with generic entry and de facto abandonment of patent rights, has revealed the extremely limited role of drug prices and access in the face of fundamental problems in infrastructure, prevention, and other essential elements in battling HIV/AIDS. Adoption of a stakeholder approach is likely to undermine essential research and development while doing little to curtail the HIV/AIDS epidemic.
AltmanLawrence K. (2004), “AIDS Drugs’ Fast Rise in Asia Risks Resistant Strains,”The New York Times, (July 8), 1.
3.
AngellMarcia (2004), “The Truth About the Drug Companies,”New York Review of Books, 51 (July 15).
4.
AttaranAmir (2004), Personal correspondence with Roger Bate regarding Botswana's government AIDS budget spending.
5.
AttaranAmir, and Gillespie-WhiteLee (2001), “Do Patents for Anti-retroviral Drugs Constrain Access to AIDS Treatment in Africa?”Journal of the American Medical Association, 286 (October 17), 1886–92.
6.
BateRoger (2003), “Saving Lives Today and Tomorrow,” working paper, Africa Fighting Malaria, [available at http://www.fightingmalaria.org].
7.
BateRoger, and TrenRichard (2004), “The Real Obstacles to Sound Treatment of AIDS in Poor Countries,”AEI Health Policy Outlook, (July–August), (accessed August 10, 2004), [available at http://www.aei.org/publication20841].
8.
BlockRobert, and HarrisGardiner (2001), “Pharmaceutical Makers Agree to Settle Patent Suit on South Africa's Terms,”The Wall Street Journal, (April 18).
9.
BrughaRuair, DonoghueMartine, StarlingMary, NdubaniPhillimon, SsengoobaFreddie, FernandesBenedita, and WaltGill (2004), “The Global Fund: Managing Great Expectations,”Lancet, 364 (July 3), 95–100.
10.
Business Day (South Africa) (2004), “Tshabalala-Msimang Renews Attack on Anti-AIDS Drug,” (July 12), 3.
11.
CarrollRory (2002), “Look What Bush Is Doing. He Could Invade,”The Guardian, (December 17), 10.
12.
CauvinHenri E. (2001), “South Africa to Appeal Ruling Ordering Access to AIDS Drug,”New York Times, (December 20), 5.
13.
ClavelFranois, and HanceAllan J. (2004), “HIV Drug Resistance,”New England Journal of Medicine, 350 (March 4), 1023–35.
14.
CohenJon (2001), Shots in the Dark: The Wayward Search for an AIDS Vaccine.New York: W.W. Norton.
15.
CohenJon (2002), “Confronting the Limits of Success,”Science, 296 (5577), 2320–24.
16.
CoovadiaHoosen (2004), “Antiretroviral Agents: How Best to Protect Infants from HIV and Save Their Mothers from AIDS,”New England Journal of Medicine, 351 (July 15), 289–92.
17.
CoplanPaul M., MitchnickMark, and RosenbergZeda F. (2004), “Regulatory Challenges in Microbiocide Development,”Science, 304 (June 25), 1911–12.
18.
DanzonPatricia M., and FurukawaMichael F. (2003), “Prices and Availability of Pharmaceuticals: Evidence from Nine Countries,”Health Affairs, (October 29), w3521–36, (accessed August 10, 2004), [available at http://knowledge.wharton.upenn.edu/papers/1210.pdf].
19.
DanzonPatricia M., and TowseAdrian (2003), “Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents,”International Journal of Health Care Finance and Economics, 3, 183–205.
20.
DiMasiJoseph A., HansenRonald W., and GrabowskiHenry G. (2003), “The Price of Innovation: New Estimates of Drug Development Costs,”Journal of Health Economics, 22 (2), 151–85.
21.
EberstadtNicholas (2002), “The Future of AIDS,”Foreign Affairs, 81 (6), 22–45.
22.
The Economist (2003), “AIDS: A Mixed Prognosis,” (November 27), 77–79.
23.
The Economist (2004), “More Money, More Problems,” (July 16).
24.
EXPLORE Study Team (2004), “Effects of a Behavioural Intervention to Reduce Acquisition of HIV Infection Among Men Who Have Sex with Men: The EXPLORE Randomised Controlled Study,”Lancet, 364 (July 3), 41–50.
FlemingCharles, and MoriceAnne-Michele (2004), “Europe Ends Soft Stance on Hard Prescription Drugs,”The Wall Street Journal, (February 25).
27.
FrankRichard G. (2003), “Government Commitment and Regulation of Prescription Drugs,”Health Affairs, 22 (May-June), 46–48.
28.
GayleHelene, and LangeJoep M.A. (2004), “Seizing the Opportunity to Capitalise on the Growing Access to HIV Treatment to Expand HIV Prevention,”Lancet, 364 (July 3), 6–7.
29.
GooznerMerrill (2004), The $800 Million Pill: The Truth Behind the Cost of New Drugs.Berkeley: University of California Press.
30.
GottliebMichael S. (2001), “AIDS—Past and Future,”New England Journal of Medicine, 344 (June 7), 1788–91.
31.
GrabowskiHenry G., VernonJohn, and DiMasiJoseph (2002), “Returns on Research and Development for 1990s New Drug Introductions,”Pharmacoeconomics, 20 (Supplement 3), 11–29.
32.
GutierrezJuan Pablo, JohnsBenjamin, AdamTaghreed, BertozziStefano M., EdejerTessa Tan-Torres, GreenerRobert, HankinsCatherine, and EvansDavid B. (2004), “Achieving the WHO/UNAIDS Antiretroviral Treatment 3 by 5 Goal: What Will It Cost?”Lancet, 364 (July 3), 63–64.
33.
HalperinDaniel, and EpsteinHelen (2004), “Concurrent Sexual Partnerships Help to Explain Africa's High HIV Prevalence: Implications for Prevention,”Lancet, 364 (July 3), 95–100.
34.
HubbardTim, and LoveJames (2004), “A New Trade Framework for Global Healthcare R&D,”PloS Biology, 2 (February), 147–50.
International AIDS Vaccine Initiative (2004), “Scientific Blueprint 2004: Accelerating Global Efforts in AIDS Vaccine Research and Development,” (accessed August 10, 2004), [available at http://www.iavi.org/pdf/IAVIScientificBlueprint2004.pdf].
37.
JourdainGonzague, Ngo-Giang-HuongNicole, Le CoeurSophie, BowonwatanuwongChureeratana, KantipongPacharee, LeechanachaiPranee, AriyadejSurabhon, LeenasirimakulPrattana, HammerScott, and LallemantMarc (2004), “Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy,”New England Journal of Medicine, 351 (July 15), 229–40.
38.
Journal of Research in Pharmaceutical Economics (2001), “Prescription Drugs Under Medicare: The Legacy of the Task Force on Prescription Drugs, Part I,”10 (Special Issue, 2 and 3).
39.
KanavosPanos (2002), “Overview of Pharmaceutical Pricing and Reimbursement Regulation in Europe,” London School of Economics, Health and Social Care, (accessed August 10, 2004), [available at http://pharmacos.eudra.org/F3/g10/docs/synthesis.pdf].
40.
KennedyCharles R., FrederickH.deB. Harris, and LordMichael D., (2004), “Integrating Public Policy and Public Affairs in a Pharmaceutical Marketing Program: The AIDS Pandemic,”Journal of Public Policy & Marketing, 23 (Fall), 128–39.
41.
KremerMichael (2002), “Pharmaceuticals and the Developing World,”Journal of Economic Perspectives, 16 (Fall), 67–90.
42.
KumarasamyN. (2003), “Generic Antiretroviral Drugs—Will They Be the Answer to HIV in the Developing World?”Lancet, 364 (July 3), 3–4.
43.
LaFraniereSharon (2004), “South Africa Rejects Use of AIDS Drug for Women,”New York Times, (July 14), 11.
44.
Lancet (2004), “HIV/AIDS: Not One Epidemic but Many,”364 (9428), 1–2.
45.
LandersPeter, and LublinJoann S. (2003), “Merck's Big Bet on Research by Its Scientists Comes Up Short: Merck Announces Drugs in Trials to Allay Fears,”The Wall Street Journal, (November 28), A1.
46.
LichtenbergFrank R., and PhilipsonTomas J. (2002), “The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry,”Journal of Law and Economics, 45 (October), 643–72.
47.
Low-BeerDaniel (2004), “Review of Rethinking AIDS Prevention, by Edward C. Green,”Lancet, 364 (July 3), 19–20.
48.
MaderIan (2004), “HIV Effort Has ‘Failed’ the Poor, Group Claims,”Atlanta Journal-Constitution, (July 14).
49.
MahmoudAdel (2004), “Editorial: The Global Vaccination Gap,”Science, 305 (July 9), 147.
MersonMichael (2001), “Review of Shots in the Dark: The Wayward Search for an AIDS Vaccine, by Jon Cohen,”New England Journal of Medicine, 344 (June 7), 1801–1802.
NakashimaEllen, and BrownDavid (2004), “AIDS Meeting Focuses on Prevention: Bangkok Conference Ends Amid Debate on Progress and Funding of Methods,”Washington Post, (July 17), A13.
56.
NamHeeSeob, and ParkSungHo (2002), “Petition Submitted by HeeSeob Nam and SungHo Park on January 30, 2002, on behalf of People's Health Coalition for Equitable Society, Association of Physicians for Humanism, and Korean Pharmacists for Democratic Society,” (accessed June 27, 2004), [available at http://glivec.jinbo.net/Request_for_CL_Final_version.htm].
57.
New York Times (2001), “Editorial: South Africa's Failure on AIDS,” (June 21), 24.
58.
PalellaFrank J., DelaneyKathleen M., MoormanAnne C., LovelessMark O., FuhrerJack, SattenGlen A., AschmanDiane J., HolmbergScott D. (1998), “Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection,”New England Journal of Medicine, 338 (March 26), 853–60.
59.
PhRMA (2001), “Drug Companies Suspend Action Against South African Law,” press release, (April 18).
ReekieW. Duncan (1997), “How Competition Lowers the Cost of Medicines,”Cuadernos de Derects Europeu Farmaceutico, 3 (8), 35–48. Reprinted in Pharmacoeconomics, 14, 107–113.
62.
ReiselWilliam, and SamaLinda (2003), “The Distribution of Life-Saving Pharmaceuticals: Viewing the Conflict Between Social Efficiency—Economic Efficiency Through a Social Contact Lens,”Business and Society Review, 108 (3), 365–87.
63.
RuxrungthamKiat, BrownTim, and PhanuphakpPraphan (2004), “HIV/AIDS in Asia,”Lancet, 364 (July 3), 69–82.
64.
SandeMerle A., and RonaldAllan (2004), “Editorial: Treatment of HIV/AIDS: Do the Dilemmas Only Increase?”Journal of the American Medical Association, 292 (2), 166–68.
65.
SchoofsMark (2001), “South Africa Won't Provide AIDS Drugs in Hospitals,”The New York Times, (June 28).
66.
ShrettaR., WaltG., BrughaR., and SnowR.W. (2001), “A Political Analysis of Corporate Drug Donations: The Example of Malarone in Kenya,”Health Policy and Planning, 16 (2), 161–70.
67.
SlaterJoanna (2003), “India's Drug Makers Emerge as Important Industry Rivals,”The Wall Street Journal, (November 13).
68.
SpilkerBert (1994), Multinational Pharmaceutical Companies: Principles and Practices, 2d ed. New York: Raven Press.
69.
StebbingJustin, GazzardB., and DouekDaniel C. (2004), “Mechanisms of Disease: Where Does HIV Live?”New England Journal of Medicine, 350 (April 29), 1872–80.
70.
StolteIneke G., DukersNicole, GeskusRonald B., CoutinhoRoel, and WitJohn Bfde (2004), “Homosexual Men Change to Risky Sex When Perceiving Less Threat of HIV/AIDS Since Availability of Highly Active Antiretroviral Therapy: A Longitudinal Study,”AIDS, 18 (January 23), 303–309.
71.
Sunday Times (Johannesburg) (2004), “Eastern Cape to Blame for Health Crisis,” (July 3).
TREAT Asia (2004), “Expanded Availability of HIV/AIDS Drugs in Asia Creates Urgent Need for Trained Doctors,” (accessed August 10, 2004), [available at http://web.amfar.org/treatment/news/TADoc7.pdf].
UNAIDS (2004), 2004 Report on the Global AIDS Epidemic.Geneva, Switzerland: UNAIDS.
76.
United Nations Development Programme (2004), Human Development Report 2004.New York: United Nations Development Programme.
77.
U.S. Department of Health, Education and Welfare (1968), Task Force on Prescription Drugs, Background Papers, “The Drugs Makers and the Drug Distributors,” (December), 25–36.
78.
The Wall Street Journal (2004), “Generic AIDS Pill Gets Patent in Africa,” (July 13), D3.
79.
WennbergJohn E., FisherElliott S., and SkinnerJonathan S. (2002), “Geography and the Debate over Medicare Reform,”Health Affairs, (February 13), W96–114, (accessed August 10, 2004), [available at http://content.healthaffairs.org/cgi/reprint/hlthaff.w2.96v1.pdf].
80.
WilsonJennifer (2004), “Cheaper Drugs in Foreign Markets Increase the Focus on Domestic Drug Prices,”Annals of Internal Medicine, 140 (April 20), 677–80.
